There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TFPI


Brief Information

Name:Tissue factor pathway inhibitor
Target Synonym:TFPI,Tissue Factor Pathway Inhibitor,Extrinsic Pathway Inhibitor,TFPI1,LACI,EPI,Anti-Convertin,TFI,Lipoprotein-associated coagulation inhibitor,Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor)
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Synonym Name



Tissue factor pathway inhibitor (TFPI) is also known as Extrinsic pathway inhibitor (EPI), Lipoprotein - associated coagulation inhibitor (LACI), is a plasma proteinase inhibitor synthesized by vascular endothelial cells and part of it is associated with glycosaminoglycans of these cells. TFPI is a single-chain polypeptide which can reversibly inhibit Factor Xa (Xa) and Thrombin (Factor IIa). TFPI is a secreted protein with a N­terminal acidic region, three Kunitz (K) domains separated with by two linker regions, and a C­terminal basic region. The first K domain inhibits coagulation factor VIIa complexed to tissue factor (TF); The second K domain inhibits factor Xa; The third K domain binds to heparin; The C­terminal basic region may have several functions. For example, it plays an important role in binding of TFPI to cell surfaces.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
BAY-1093884 BAY-109; BAY-1093884 Phase 2 Clinical Morphosys Ag, Bayer Ag Hemophilia A; Hemophilia B Details
Concizumab NN-7415; mAb-2021; Anti-TFPI; mAbTFPI2021; NNC-172-2021; NNC-0172-2021; NNC-0172-0000-2021 Phase 3 Clinical Novo Nordisk A/S Hemophilia A; Hemophilia B; Hemorrhage Details
Marstacimab PF-6741086; PF-06741086 Phase 3 Clinical Pfizer Pharmaceuticals Ltd (China) Hemophilia A; Hemophilia B; Hemorrhage Details

This web search service is supported by Google Inc.